Interstitial lung disease associated with gefitinib-Reference-Cited by-同舟云学术

Interstitial lung disease associated with gefitinib

Published:2006-04 Issue:4 Volume:100 Page:698-704
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Kataoka Kensuke,Taniguchi Hiroyuki,Hasegawa Yoshinori,Kondoh Yasuhiro,Kimura Tomoki,Nishiyama Osamu,Imaizumi Kazuyoshi,Kawabe Tsutomu,Kume Hiroaki,Shimokata Kaoru

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference22 articles.

1. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial;Herbst;J Clin Oncol,2002

2. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer;Fukuoka;J Clin Oncol,2003

3. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program;Pallis;Lung Cancer,2003

4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

5. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung cancer and idiopathic pulmonary fibrosis: environmental exposures are the key;European Respiratory Journal;2024-05

2. Successful rechallenge twice with different EGFR-TKIs in a patient with lung adenocarcinoma after EGFR- TKI-induced grade 3 stomatitis and interstitial lung disease: a case report;2024-04-03

3. <i>Mesenchymal-epithelial transition</i> Exon 14-Skipping Mutation-positive Invasive Mucinous Adenocarcinoma of the Lung: First Case Treated with Mesenchymal-epithelial Transition-tyrosine Kinase Inhibitors;Internal Medicine;2024

4. Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats;Saudi Journal of Biological Sciences;2023-02

5. Image-guided drug delivery of nanotheranostics for targeted lung cancer therapy;Theranostics;2022